We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
- Authors
Mori, Ryusaburo; Honda, Shigeru; Gomi, Fumi; Tsujikawa, Akitaka; Koizumi, Hideki; Ochi, Haruka; Ohsawa, Shino; Okada, Annabelle Ayame
- Abstract
In the original publication, incorrect Supplementary Material has been published. The online version of the original article can be found at https://doi.org/10.1007/s10384-023-00985-w.
- Subjects
JAPAN; MACULAR degeneration; CLINICAL trials; DURABILITY
- Publication
Japanese Journal of Ophthalmology, 2023, Vol 67, Issue 3, p311
- ISSN
0021-5155
- Publication type
Correction Notice
- DOI
10.1007/s10384-023-00996-7